Search hospitals > Texas > Lubbock
UMC Cancer Center / UMC Health System
Claim this profileLubbock, Texas 79415
Global Leader in Tumors
Global Leader in Lymphoma
Conducts research for Leukemia
Conducts research for Cancer
Conducts research for Acute Lymphoblastic Leukemia
55 reported clinical trials
3 medical researchers
Summary
UMC Cancer Center / UMC Health System is a medical facility located in Lubbock, Texas. This center is recognized for care of Tumors, Lymphoma, Leukemia, Cancer, Acute Lymphoblastic Leukemia and other specialties. UMC Cancer Center / UMC Health System is involved with conducting 55 clinical trials across 200 conditions. There are 3 research doctors associated with this hospital, such as Erin K. Barr, Mohamad M. Al-Rahawan, and Karla A. Daniele.Area of expertise
1Tumors
Global LeaderStage IV
Stage I
Stage II
2Lymphoma
Global LeaderStage IV
Stage II
Stage III
Top PIs
Erin K. BarrUMC Cancer Center / UMC Health System7 years of reported clinical research
Studies Tumors
Studies Lymphoma
32 reported clinical trials
87 drugs studied
Mohamad M. Al-RahawanUMC Cancer Center / UMC Health System7 years of reported clinical research
Studies Tumors
Studies Cancer
23 reported clinical trials
74 drugs studied
Karla A. DanieleUMC Cancer Center / UMC Health System3 years of reported clinical research
Studies Breast Cancer
Studies Recurrence
1 reported clinical trial
5 drugs studied
Clinical Trials running at UMC Cancer Center / UMC Health System
Breast Cancer
Osteosarcoma
Germ Cell Tumors
Rhabdomyosarcoma
Acute Lymphoblastic Leukemia
Brain Tumor
Non-Hodgkin's Lymphoma
Ovarian Tumors
Lymphoma
Testicular Carcinoma
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at UMC Cancer Center / UMC Health System?
UMC Cancer Center / UMC Health System is a medical facility located in Lubbock, Texas. This center is recognized for care of Tumors, Lymphoma, Leukemia, Cancer, Acute Lymphoblastic Leukemia and other specialties. UMC Cancer Center / UMC Health System is involved with conducting 55 clinical trials across 200 conditions. There are 3 research doctors associated with this hospital, such as Erin K. Barr, Mohamad M. Al-Rahawan, and Karla A. Daniele.